SS
GRTX

Steve Schonfeld’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Steve Schonfeld’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-147,300
Closed -$460K – 2447
2023
Q2 		$460K Buy
147,300
+11,200
+8% +$33.3K ﹤0.01% 1253
2023
Q1 		$348K Buy
+136,100
New +$281K ﹤0.01% 1310
2022
Q2 		– Sell
-26,600
Closed -$63K – 3143
2022
Q1 		$63K Buy
+26,600
New +$69.3K ﹤0.01% 2311
2021
Q2 		– Sell
-54,488
Closed -$481K – 2407
2021
Q1 		$481K Buy
+54,488
New +$598K 0.01% 1159

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Steve Schonfeld's GRTX Position: Q3 2023 in Review

Steve Schonfeld sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q3 2023, closing a stake of 147,300 shares — an estimated $460K sold.

Steve Schonfeld first reported a position in GRTX in Q1 2021 and held it in 4 quarters. The position peaked at $481K in Q1 2021. 38 funds tracked by Wall St. Rank hold GRTX as of Q3 2023.

  • Steve Schonfeld reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Steve Schonfeld sold 147,300 Galera Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $460K.
  • Steve Schonfeld first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Steve Schonfeld's Galera Therapeutics, Inc. Common Stock position peaked at $481K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.